Securities Code: 002370 Securities Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-034
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Announcement on Disposal of Part of Non-current Financial Assets
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Asia-Pacific Pharmaceutical") held its Eighth Board of Directors' Twelfth Meeting on April 23, 2026, which deliberated and passed the "Proposal on Disposal of Part of Non-current Financial Assets." The relevant matters are hereby announced as follows:
I. Transaction Overview
(I) Overview of This Transaction
To further optimize the Company's asset liquidity, the Company plans to dispose of other non-current financial assets measured at fair value as listed in the 2025 annual report, based on securities market conditions and actual development needs. The Company's holding of the aforementioned financial assets has clear ownership, is not subject to any mortgage, pledge, or other third-party rights, and does not involve any major disputes, litigation, or arbitration matters, nor is it subject to seizure, freezing, or other similar situations.
(II) Approval Procedures
On April 23, 2026, the Company held the Eighth Board of Directors' Twelfth Meeting. The meeting deliberated and passed the "Proposal on Disposal of Part of Non-current Financial Assets" with 9 votes in favor, 0 votes against, and 0 abstentions. The Board of Directors authorized the Company's management, within its scope of authority, to dispose of other non-current financial assets measured at fair value as listed in the 2025 annual report, based on securities market conditions and actual development needs, under conditions where risks are controllable and the Company's normal operations are not affected. This authorization is valid for 12 months from the date of deliberation and approval by the Board of Directors.